National Cancer Institute Funds Second Year Of Grant To Guided Therapeutics To Commercialize Non-invasive Cervical Cancer Detection Device

Main Category: Cervical Cancer / HPV Vaccine
Also Included In: Medical Devices / Diagnostics
Article Date: 26 Aug 2010 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Guided Therapeutics, Inc. (GT) (OTCBB: GTHP) announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.

The three-year grant provides additional resources to commercialize and bring to market the LightTouch™ non-invasive cervical cancer detection device and single-patient-use disposable.

"The continuation of the grant provides additional non-dilutive resources for us to complete the regulatory process, include design enhancements and begin manufacturing LightTouch devices and disposables," said Mark L. Faupel, Ph.D., President and CEO of GT. "We believe that the award continuation also indicates a high level of confidence in our technology by the NCI reviewers."

GT has been awarded approximately $6 million in six consecutive grants from the NCI to develop the new, pain-free test for detecting cervical disease.

The GT LightTouch technology scans the cervix with light to identify cancer and pre-cancer painlessly and non-invasively. The technology distinguishes between normal and diseased tissue, by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the LightTouch test does not require a tissue sample or laboratory analysis, and is designed to provide results immediately. The technology is designed as a device employing a single-use disposable patient interface.

Results of a multi-center pivotal clinical trial showed that LightTouch detected cervical disease up to two years earlier than Pap test, HPV test, colposcopy and biopsy. The LightTouch is designed to detect disease early, when treatment is most effective, and to eliminate unnecessary testing saving the healthcare system money.

Source:
Guided Therapeutics

Article adapted by Medical News Today from original press release.
Visit our cervical cancer / hpv vaccine section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Guided Therapeutics. "National Cancer Institute Funds Second Year Of Grant To Guided Therapeutics To Commercialize Non-invasive Cervical Cancer Detection Device." Medical News Today. MediLexicon, Intl., 26 Aug. 2010. Web.
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/198944.php>

APA
Guided Therapeutics. (2010, August 26). "National Cancer Institute Funds Second Year Of Grant To Guided Therapeutics To Commercialize Non-invasive Cervical Cancer Detection Device." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/198944.php.

Please note: If no author information is provided, the source is cited instead.


Cervical Cancer / HPV Vaccine

Most Popular Articles



Follow Our Cervical Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cervical Cancer / HPV Vaccine Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »